Several chemical disinfectants have been tested in a quantitative suspension test for virucidal activity as per the test method devised by the
(effective against enveloped viruses) in addition to the existing term "virucidal activity" (effective against non-enveloped and enveloped vir-2 Institute for Microbiology and Virology at the University Wituses) by the Robert Koch Institute has led to enormous expansion of these tests. However, there are no definitions to determine when a ten/Herdecke, Witten, Germany disinfectant with virucidal activity as apposed to a disinfectant with limited virucidal activity is to be used. The 1982 guideline was recently revised, while bringing it into line to reflect the latest insights. The BSA challenge has been omitted, while other controls such as verification of the sustained effect and interference control with which cell susceptibility is verified have been incorporated. A new requirement is that all tests be conducted in at least two independent batches, followed by biometric evaluation of the test results with calculation of the 95% confidence interval. The new guideline differs from DIN EN 14476, which in the meantime has been published in Europe, in that it does not feature the statistics now required. This guideline has introduced the parvovirus for chemothermal inactivation as well as the Bovine Viral Diarrhea Virus (BVDV) as test virus for the limited virucidal activity (in addition to vaccinia virus which serves as a surrogate virus for hepatitis C virus -HCV). A second important example is Feline Calicivirus (FCV), which serves as a surrogate for noroviruses. In the USA efficacy testing of surface disinfectants against noroviruses is conducted with FCV in a carrier test (practice-related test). The third surrogate virus is the Duck Hepatitis B Virus (DHBV), used as a surrogate for hepatitis B virus (HBV). Today evaluation of the virus-inactivating properties is often conducted in parallel with bacteriological evaluation, so as to avoid any subsequent surprises in respect of viral efficacy. The DVV has failed over the past 24 years to formulate guidelines for practice-oriented tests. The future challenge is to define these as quickly as possible. Here similar approaches should be used for e.g. process challenge devices, challenge, exposure time as for bacteriological evaluation, so that the resultant application recommendations have equivalent status. The term "limited virucidal activity" should be expanded to disinfectant efficacy at European level.
Zusammenfassung
Viele [3] has led to enormous expansion of these tests in the past year and a half. However, at present there are no definitions to determine when a disinfectant with virucidal activity as apposed to a disinfectant with limited virucidal activity is to be used. The 1982 guideline was recently revised by the specialist committee "Viral Disinfection" at the DVV under the direction of Prof. Rabenau, while bringing it into line to reflect the latest insights [4] . The version of the newly named guideline (name changed for legal reasons) first published in December 2005 by the DVV and RKI dates back to 15 June 2005. The most important differences relate to the omission of the BSA load as well as the incorporation of other controls such as verification of the sustained effect and interference control with which cell susceptibility is verified. A new requirement is that all tests be conducted in at least two independent batches, followed by biometric evaluation of the test results with calculation of the 95% confidence interval. The new guideline differs from DIN EN 14476, which in the meantime has been published in Europe and does not call for biometric evaluation, in particular in respect of the statistical calculations now specified [5] . This guideline has introduced parvovirus for chemothermal inactivation. For the first time this guideline also cites Bovine Viral Diarrhea Virus (BVDV) as test virus for the limited virucidal activity (in addition to vaccinia virus), which serves as a surrogate virus for hepatitis C virus (HCV Often today, evaluation of virus-inactivating properties is already a component of development activities in parallel to bacteriological tasks following a situation whereby in the past many chemical disinfectants were optimized only for efficacy against bacteria and fungi, giving rise to later surprises in respect of viral efficacy when testing the products available on the market. However, over the past 24 years the DVV has failed to formulate guidelines for practice-oriented tests since in the last analysis quantitative suspension tests have merely an orientational character and the application recommendations must be tailored to the results of practical tests.
Here it should be borne in mind that in many respects, e.g. process challenge devices, challenge, exposure times, similar approaches are used as for bacteriological evaluation so that the resultant application recommendations have equivalent status. Top priority for the time being must be accorded to the formulation of practice-oriented test guidelines, and attempts must be made to achieve this as soon as possible. This will give the user of chemical disinfectants a greater sense of security in his efforts to interrupt viral infection chains in the hospital and medical practice and to provide better protection to patients and staff. Surrogate viruses can play an important role in testing and be integrated into test guidelines. Once the corresponding indications have been defined, the term "limited virucidal activity" should be expanded to disinfectant efficacy at European level.
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